The first two authors contributed equally to this work.
Cancer Cell Biology
A panel of p16INK4A, MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma
Article first published online: 16 SEP 2008
Copyright © 2008 Wiley-Liss, Inc.
International Journal of Cancer
Volume 123, Issue 12, pages 2767–2773, 15 December 2008
How to Cite
Hoevenaars, B. M., van der Avoort, I. A.M., de Wilde, P. C.M., Massuger, L. F.A.G., Melchers, W. J.G., de Hullu, J. A. and Bulten, J. (2008), A panel of p16INK4A, MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma. Int. J. Cancer, 123: 2767–2773. doi: 10.1002/ijc.23857
- Issue published online: 15 OCT 2008
- Article first published online: 16 SEP 2008
- Manuscript Accepted: 26 JUN 2008
- Manuscript Received: 21 NOV 2007
- vulvar carcinoma;
- vulvar intraepithelial neoplasia;
Two pathways leading to vulvar squamous cell carcinoma (SCC) exist. The expression of proliferation- and cell-cycle-related biomarkers and the presence of high-risk (hr) HPV might be helpful to distinguish the premalignancies in both pathways. Seventy-five differentiated vulvar intra-epithelial neoplasia (VIN)-lesions with adjacent SCC and 45 usual VIN-lesions (32 solitary and 13 with adjacent SCC) were selected, and tested for hr-HPV DNA, using a broad-spectrum HPV detection/genotyping assay (SPF10-LiPA), and the immunohistochemical expression of MIB1, p16INK4A and p53. All differentiated VIN-lesions were hr-HPV- and p16-negative and in 96% MIB1-expression was confined to the parabasal layers. Eighty-four percent exhibited high p53 labeling indices, sometimes with parabasal extension. Eighty percent of all usual VIN-lesions were hr-HPV-positive, p16-positive, MIB1-positive and p53-negative. Five (of seven) HPV-negative usual VIN lesions, had an expression pattern like the other HPV-positive usual VIN lesions. In conclusion, both pathways leading to vulvar SCC have their own immunohistochemical profile, which can be used to distinguish the 2 types of VIN, but cannot explain differences in malignant potential. © 2008 Wiley-Liss, Inc.